Entera Bio Reports $3.5 Million Net Loss in Q1 2026, No Revenue Generated

Entera Bio Ltd. reported its financial results for the first quarter of 2026, revealing a net loss of $3.5 million, an increase from the $2.6 million loss recorded in the same period of 2025. The company did not generate any revenue during the quarter, a decline from $42,000 in the previous year, as it completed its obligations under a research services agreement. Operating expenses rose to $3.5 million, primarily driven by a significant increase in research and development costs, which reached $2.3 million compared to $1.1 million in the prior year. This increase reflects ongoing investments in the development of its product candidates, particularly EB613 for osteoporosis and EB612 for hypoparathyroidism.

As of March 31, 2026, Entera Bio's total assets amounted to $13.1 million, a decrease from $16.0 million at the end of 2025. The company's cash and cash equivalents stood at $4.1 million, down from $7.1 million, while restricted cash increased slightly to $7.8 million. The accumulated deficit reached $128.9 million, highlighting the ongoing financial challenges faced by the company as it continues to invest heavily in research and development without generating significant revenue.

Strategically, Entera Bio has made notable advancements in its product pipeline. In February 2026, the company submitted a clinical amendment to the FDA for its EB613 Phase 3 protocol, which is intended to be the first oral treatment for post-menopausal osteoporosis. Additionally, the company expanded its collaboration with OPKO Biologics to include the development of a long-acting PTH analog for hypoparathyroidism, further diversifying its product offerings. The company also completed a private placement in April 2026, raising approximately $10 million to support its ongoing operations and clinical studies.

Operationally, Entera Bio's workforce remained stable with 22 employees as of March 31, 2026, all based in Israel. The company continues to focus on its N-Tab® platform, which aims to facilitate the oral delivery of peptide therapies, addressing significant unmet needs in chronic medical conditions. Despite the geopolitical tensions in the region, the company reported that its operations have not been materially affected, and it remains committed to advancing its clinical programs.

Looking ahead, Entera Bio anticipates that its existing cash resources, bolstered by the recent private placement, will be sufficient to fund its operations through the first quarter of 2027. However, the company acknowledges the need for additional funding to fully support its Phase 3 clinical study of EB613 and other development activities. The management continues to explore various financing options, including public and private equity offerings, to ensure the sustainability of its operations and the advancement of its product candidates.